Physician profile
Ramya Raghavan
NPI 1952899155
$4,501.73
in general payments reported to CMS, 2019-2025
29 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $200 · 2021: $1,235 · 2022: $772 · 2023: $831 · 2024: $522 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.07 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $430.13 | 2019-2024 | Ultomiris |
| Biogen, INC. | $401.84 | 2020-2021 | |
| Ucb, INC. | $392.30 | 2023 | Briviact, Nayzilam |
| Biohaven Pharmaceuticals, INC. | $385.66 | 2021 | |
| Sk Life Science, INC. | $257.96 | 2023-2025 | Xcopri |
| Genentech USA, INC. | $254.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $243.67 | 2022 | |
| Acorda Therapeutics, INC | $144.34 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $139.35 | 2019-2021 | |
| Genzyme Corporation | $128.56 | 2022 | |
| Insightec,INC | $102.69 | 2023 | Exablate |
| Neuropace, INC. | $92.39 | 2024 | |
| Lundbeck LLC | $88.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.53 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.62 | 2021-2025 | Kisunla, Amyvid |
| Horizon Therapeutics Plc | $45.74 | 2022 | |
| Supernus Pharmaceuticals, INC. | $43.17 | 2021-2022 | |
| Csl Behring | $42.15 | 2020-2021 | |
| Mdd US Operations, LLC | $41.11 | 2024 | Apokyn |
| Adamas Pharmaceuticals, INC. | $39.16 | 2021 | |
| Acadia Pharmaceuticals INC | $37.16 | 2021 | |
| Avanir Pharmaceuticals, INC. | $35.17 | 2019 | |
| Neurocrine Biosciences, INC. | $29.37 | 2020 | |
| Kyowa Kirin, INC. | $23.17 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.58 | 2020 | |
| Pfizer INC. | $15.29 | 2024 | |
| Eisai INC. | $12.66 | 2021 | |
| Emd Serono, INC. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramya Raghavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.